| (Values in U.S. Thousands) | Dec, 2023 | Sep, 2023 | Jun, 2023 | Dec, 2022 | Sep, 2022 |
| Sales | 492 | 594 | 600 | 522 | 489 |
| Sales Growth | -17.11% | -1.02% | +14.89% | +6.84% | +7.40% |
| Net Income | -907 | -273 | -802 | -7,658 | -2,171 |
| Net Income Growth | -232.46% | +65.99% | +89.52% | -252.77% | +7.39% |
Braxia Scientific Corp (BRAX.CN)
N/A x N/A 0.0600 x 1000
Pre-market by (Cboe BZX)
0.0050 unch (unch) 08/02/24 [CNSX]
N/A x N/A 0.0600 x 1000
Pre-market 0.0050 unch (unch) -
for Fri, Aug 2nd, 2024
Braxia Scientific Corp is a research-driven medical solutions company that aims to reduce the illness burden of brain-based mental disorders such as depressive disorder among others. It is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing novel drugs and delivery methods. The company develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform.
Fiscal Year End Date: 03/31